PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Ранг среди акций #1442
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Цена акции
$36.89
Рыночная капитализация
$15.25B
Изменение (1 день)
-1.28%
Изменение (1 год)
144.12%
Страна
TW
Торговля PharmaEssentia Corporation (6446)

Категория

Healthcare
Коэффициент P/B для PharmaEssentia Corporation (6446)
Коэффициент P/B на October 2026 TTM: 13.50
Согласно последним финансовым отчетам и цене акций PharmaEssentia Corporation, текущий коэффициент P/B (TTM) составляет 13.50. В конце 2023 он составлял 4.70.
История P/B для PharmaEssentia Corporation с 2010 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
2026 (TTM) 13.50 85.23%
2024 7.29 54.92%
2023 4.70 -57.85%
2022 11.16 -36.95%
2021 17.70 205.50%
2020 5.79 -44.22%
2019 10.39 -30.22%
2018 14.88 65.96%
2017 8.97 16.17%
2016 7.72 -85.09%
2015 51.79 198.70%
2014 17.34 0.82%
2013 17.20 -64.44%
2012 48.36 -92.11%
2011 613.14 490.71%
2010 103.80 0.00%
Коэффициент P/B для аналогичных компаний или конкурентов